Therefore, this study was designed to identify whether luteolin could ameliorate sympathetic activation and hypertension in SHRs, and whether NF-κB-mediated inflammation and PI3K/Akt signaling pathway within PVN participate in the central molecular anti-hypertensive mechanisms of luteolin. This evidence concerns the gene NFKB1 and Hypertension.